Current reports
6-K
Cardiol Therapeutics Announces Year-End 2023 Update on Operations
2 Apr 24
6-K
Material Change Report
26 Feb 24
6-K
Cardiol Therapeutics Completes Patient Enrollment in its Phase II
21 Feb 24
6-K
Cardiol Therapeutics Granted Orphan Drug Designation for its
15 Feb 24
6-K
Current report (foreign)
24 Jan 24
6-K
Cardiol Therapeutics Announces it has Exceeded
9 Jan 24
6-K
MAvERIC-Pilot is a Phase II Study in Recurrent Pericarditis and is Anticipated to Complete Patient Recruitment during Q1 2024
5 Dec 23
6-K
Cardiol Therapeutics Announces Study Results Presented at the 2023 Annual Meeting of the European Society of Cardiology Working Group
16 Nov 23
6-K
Current report (foreign)
14 Nov 23
6-K
Cardiol Therapeutics Announces it has Exceeded 50% Enrollment in its
1 Nov 23
Registration and prospectus
SUPPL
Supplemental materials (foreign)
9 Jun 22
SUPPL
Supplemental materials (foreign)
8 Feb 22
F-10POS
Automatic registration of securities (post-effective amendment, Canada)
8 Feb 22
F-10/A
Registration of securities (Canada) (amended)
8 Feb 22
F-10
Registration of securities (Canada)
26 Jan 22
F-X
Appointment of agent for service of process by issuers registering securities
26 Jan 22
S-8
Registration of securities for employees
18 Jan 22
S-8 POS
Registration of securities for employees (post-effective amendment)
18 Jan 22
SUPPL
Supplemental materials (foreign)
4 Nov 21
SUPPL
Supplemental materials (foreign)
4 Nov 21
Proxies
No filings